Clinical outcomes of benign brain tumors treated with single fraction LINAC‑based stereotactic radiosurgery: Experience of a single institute

Tzu Chi Medical Journal

article

Chia‑Hui Chew¹  Jin‑Cherng Chen²  Shih‑Kai Hung¹  Tsung‑Hsien Wu²  Moon‑Sing Lee¹  Wen‑Yen Chiou¹  Liang‑Cheng Chen¹  Hon‑Yi Lin¹ 

[1] Department of Radiation Oncology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation;Department of Neurosurgery, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation;School of Medicine, Tzu Chi University;Institute of Molecular Biology, National Chung Cheng University

关键词: Benign brain tumor;    LINAC;    Stereotactic radiosurgery;    Tumor control rate;   

DOI  :  10.4103/tcmj.tcmj_260_21

来源: Wolters Kluwer Medknow Publications

【 摘 要 】

Objectives: Accelerator‑based stereotactic radiosurgery (SRS) is a noninvasive and effective treatment modality widely used for benign brain tumors. This study aims to report 20‑year treatment outcomes in our institute. Materials and Methods2 cm in the maximal diameter. Overall survival (OS) and adverse reaction (defined according to CTCAE 5.0) were also analyzed. Results: The present study included 76 female and 51 male patients for analysis. The median age was 59 years (range, 20–88 years). Their diagnoses were vestibular schwannoma (VS, n = 54), nonvestibular cranial nerve schwannoma (n = 6), meningioma (n = 50), and pituitary adenoma (n = 17). Totally 136 lesions were treated in a single fraction, predominantly skull base tumors, accounting for 69.1%. Median and mean follow‑up duration was 49 and 61 months (range, 1–214 months), Overall TCR was 92.9%. The 5‑year disease‑specific TCR for VS, nonvestibular schwannoma, meningioma, and pituitary adenoma were 97.4%, 91.7%, 93.8%, and 83.3%. Salvage therapy was indicated for eight patients at 4–110 months after SRS. Among symptomatic patients, post‑SRS symptom(s) was improved, stable, and worse in 68.2%, 24.3%, and 3.6%, respectively. Radiological response rate for 111 evaluable patients was 94.6% (shrinkage, 28.8%; stable, 65.8%). OS was 96.1% without treatment‑related mortality. One patient with post‑SRS cranial nerve injury (0.8%, involving the trigeminal nerve, grade 2 toxicities). No grade 3–4 acute or late toxicity was found. Conclusion: Our results suggested that LINAC‑based SRS effectively controls tumor growth and tumor‑related neurological symptoms for patients with benign brain tumors. SRS is less aggressive, associated with low neurological morbidity and no mortality. Continuous follow‑up is indicated to conclude longer outcomes.

【 授权许可】

Unknown